Plerixafor Plus Granulocyte Colony-Stimulating Factor For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Non-Hodgkin Lymphoma

NCT ID: NCT02221492

Last Updated: 2016-03-30

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 32 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-11-30
• Study Completion Date: 2016-03-31

Brief Summary

Primary Objective:

To determine if non-Hodgkin Lymphoma (NHL) participants mobilized with granulocyte colony-stimulating factor (G-CSF) plus plerixafor 240 μg/kg are more likely to achieve a target number of greater than or equal to 5 x 10^6 cluster differential (CD) 34+ cells/kg in 4 or fewer days of apheresis than NHL participants mobilized with G-CSF alone.

Secondary Objectives:

• To evaluate the safety of G-CSF plus plerixafor arm compared to G-CSF arm in NHL participants.
• To compare the 2 treatment arms with respect to the number of participants who achieved a minimum of 2 x 10^6 CD34+ cells/kg in 4 or fewer days of apheresis.
• To compare the 2 treatment arms with respect to the number of days of apheresis required to reach the target of greater than or equal to 5 x 10^6 CD34+ cells/kg.

Detailed Description

Total study duration for a participant can be approximately up to 68 days.

Conditions

Lymphoma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

granulocyte colony-stimulating factor alone

G-CSF administered up to 8 days

Group Type: ACTIVE_COMPARATOR

Filgrastim

Intervention Type: DRUG

Pharmaceutical form:vial Route of administration: subcutaneous injection

granulocyte colony-stimulating factor plus plerixafor

G-CSF administered up to 8 days (Day 1 to Day 8) and plerixafor administered for 4 days (Day 4 to Day 7)

Group Type: EXPERIMENTAL

plerixafor GZ316455

Intervention Type: DRUG

Pharmaceutical form:vial Route of administration: subcutaneous injection

Filgrastim

Intervention Type: DRUG

Pharmaceutical form:vial Route of administration: subcutaneous injection

Interventions

plerixafor GZ316455

Pharmaceutical form:vial Route of administration: subcutaneous injection

Intervention Type: DRUG

Filgrastim

Pharmaceutical form:vial Route of administration: subcutaneous injection

Intervention Type: DRUG

Other Intervention Names

Mozobil

Eligibility Criteria

Inclusion Criteria

• Age 20 to 75.
• Japanese participants with histological or pathological diagnosis of NHL.
• First or second complete response (CR) or partial response (PR).

Exclusion Criteria

• Leukemia participants.
• Myelodysplastic syndrome (MDS) participants.
• Less than 2 weeks since completion of last cycle of chemotherapy.
• Failed previous hematopoietic stem cell (HSC) collections or collection attempts.
• Prior autologous or allogeneic transplant.
• Diagnosis of another malignancy.
• Known hypersensitivity to plerixafor, G-CSF or their components.
• Bone marrow involvement greater than 5%.
• Eastern Cooperative Oncology Group (ECOG) performance status greater than 1.
• Not yet recovered from all acute toxic effects of prior Chemotherapy.
• White blood cell (WBC) count less than or equal to 2.5 × 10^9 cells/L.
• Absolute neutrophil count (ANC) less than or equal to 1.5 × 10^9 cells /L.
• Platelet count less than or equal to 100 × 10^9 cells /L.
• Creatinine clearance less than 50 mL/min.
• Aspartate aminotransferase (AST), or alanine aminotransferase (ALT) greater than or equal to 2.5 x upper limit of normal,Total Bilirubin greater than or equal to 2.5 x upper limit of normal.
• Cardiac and pulmonary status insufficient to undergo apheresis or transplantation.
• Active central nervous system (CNS) involvement, active brain metastases, or any history of carcinomatous meningitis.
• Active infection, including unexplained fever (greater than 38 degrees C), or antibiotic therapy within 7 days prior to the first dose of G-CSF.
• Less than 6 weeks off nitrosoureas prior to first dose of G-CSF.
• Conditions/situations such as received prior radio-immunotherapy with ibritumomab tiuxetan or tositumomab iodine and received radiation therapy to the pelvis.
• Significant concomitant illness, including psychiatric condition that, in the opinion of the Investigator or Sponsor, would adversely affect the participant's participation in the study.
• Abnormal electrocardiogram (ECG) with clinically significant rhythm disturbance (ventricular arrhythmias) or other conduction abnormality in the last year that, in the opinion of the Investigator(s), warrants exclusion of the participant from the trial.
• Previously received experimental therapy within 4 weeks of randomization or who are currently enrolled in another experimental protocol during the G-CSF and plerixafor treatment period.
• Any malignancy related to immunodeficiency virus (HIV) or solid organ transplant; history of known HIV, viral hepatitis as documented at the detection of hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb)[exclude patients who clearly received vaccination], hepatitis B core antibody (HBcAb), and/or hepatitis C virus (HCV) antibody at the time of the screening visit.
• Unwillingness and inability to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures, and study restrictions.
• Related to the active comparator and/or mandatory background therapies.
• Received G-CSF within 7 days prior to the first dose of G-CSF for mobilization.
• Related to the current knowledge of Sanofi compound.
• Pregnant or breast-feeding women.
• All participants, who are sexually active (males and females), must agree to an effective method of contraception while on study treatment and for at least 3 months following plerixafor treatment (including both female participants of child-bearing potential and male participants with partners of childbearing potential).
• Patient who has withdrawn consent before enrollment/randomization.
• Despite screening of the patient, enrollment/randomization is stopped at the study level.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Genzyme, a Sanofi Company

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clinical Sciences & Operations

Role: STUDY_DIRECTOR

Sanofi

Locations

Investigational Site Number 392005

Chiba, , Japan

Investigational Site Number 392011

Fukuoka, , Japan

Investigational Site Number 392014

Fukuyama-Shi, , Japan

Investigational Site Number 392010

Hamamatsu, , Japan

Investigational Site Number 392006

Kamogawa-Shi, , Japan

Investigational Site Number 392003

Kobe, , Japan

Investigational Site Number 392008

Kurashiki-Shi, , Japan

Investigational Site Number 392015

Ota-Shi, , Japan

Investigational Site Number 392004

Sapporo, , Japan

Investigational Site Number 392001

Shibuya-Ku, , Japan

Investigational Site Number 392009

Suwa-Shi, , Japan

Investigational Site Number 392007

Toyohashi, , Japan

Countries

Japan

References

Matsue K, Kumagai K, Sugiura I, Ishikawa T, Igarashi T, Sato T, Uchiyama M, Miyamoto T, Ono T, Ueda Y, Kiguchi T, Sunaga Y, Sasaki T, Suzuki K. Plerixafor for mobilization and collection of haematopoietic stem cells for autologous transplantation in Japanese patients with non-Hodgkin lymphoma: a randomized phase 2 study. Int J Hematol. 2018 Nov;108(5):524-534. doi: 10.1007/s12185-018-2505-4. Epub 2018 Jul 24.

Reference Type: DERIVED

PMID: 30043330 (View on PubMed)

Other Identifiers

ACT12781

Identifier Type: -

Identifier Source: org_study_id

U1111-1152-4309

Identifier Type: OTHER

Identifier Source: secondary_id